'Mad Money' host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
: "I think GW Pharma is real good. . Now it is, again, I keep pointing this out, is in marijuana ETFs and the shorts are pushing those down. . but GW Pharma is a true pharmaceutical company and I think it's fine.
: "I think GW Pharma is real good. ... Now it is, again, I keep pointing this out, is in marijuana ETFs and the shorts are pushing those down. ... but GW Pharma is a true pharmaceutical company and I think it's fine. Half position now, and see if the marijuana stocks have one more leg down."United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Everything Jim Cramer said about the stock market on 'Mad Money,' including Uber lockup, 'junk' Chinese IPOs, buy Twitter, Zebra CEOCNBC's Jim Cramer warns of a 'very rude awakening' due to looming lockup expirations, urges Wall Street to stop allowing 'junk' Chinese IPOs, calls Twitter's stock a buy and sits down with Zebra Technologies CEO Anders Gustafsson.
Read more »
Cramer: This biotech stock could be worth over $100 billion on an FDA approvalBiogen, with a $54.1 billion market cap, 'could be worth twice that if all goes well' with regulators, Jim Cramer says.
Read more »
Jim Cramer: Investors must consider these two critical factors affecting Facebook and Apple'I'm sensing some skepticism ... creeping in about both of them and I suspect some of it has to do with twin constraints of time and government,' CNBC's Jim Cramer says.
Read more »
Cramer's lightning round: Marvell Technology is the best play on 5G'Mad Money' host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
Read more »
Cramer: This biotech stock could be worth over $100 billion on an FDA approvalBiogen, with a $54.1 billion market cap, 'could be worth twice that if all goes well' with regulators, Jim Cramer says.
Read more »